Oncotype DX Colon Recurrence Score Report Interpreter
A source-locked guide to interpreting a final reported score using the prespecified QUASAR and NSABP C-07 score groups.
Route scope: this is a reported-score interpreter, not a genomic assay calculator or treatment recommender.
What the interpreter accepts
The permanent /calculator/oncotype-colon route requires a final Exact Sciences integer score from 0 through 100 and complete report context. It preserves the original score, stage, and mmr input IDs while explicitly checking tumor site, adenocarcinoma histology, T category, nodal group, complete resection, postoperative treatment status, result source, and final-report status.
The supported populations are:
- Stage II: T3 or T4, N0, MMR proficient.
- Stage III: the Stage III A/B population as stated on the assay report, any T category, and 1-3 positive nodes.
The route does not infer an AJCC edition or derive Stage III A/B from raw TNM fields.
Prespecified score groups
| Final reported score | Group | | --- | --- | | 0-29 | Low | | 30-40 | Intermediate | | 41-100 | High |
These are group labels, not patient-specific recurrence percentages. The interpreter does not reproduce the proprietary 12-gene calculation or report risk curves.
Official report markers
Exact Sciences materials identify two report-display markers:
- Stage II MMR-proficient score
>=41: higher-risk shading. - Stage III A/B score
<30: lower-risk shading.
The route reports whether the applicable marker is met, while explicitly separating that display marker from treatment advice.
Neutral outcomes
Invalid input: malformed object, missing or extra keys, coercive values, nonfinite values, decimals, unsupported enums, or inherited-only fields.Incomplete assessment: a required report-population field is unknown. Stage III MMR may remain unknown because score-group interpretation does not depend on MMR in that report population.Outside validated scope: a complete but excluded context, including rectal/other primary, non-adenocarcinoma, unsupported stage/T/nodes, Stage II dMMR, residual disease, postoperative treatment already started, nonfinal report, or an estimated score.
What remains outside this route
The interpreter does not calculate gene expression, the proprietary score, individualized recurrence probability, a risk curve, chemotherapy benefit, regimen selection, duration, or treatment recommendation. The actual laboratory report and multidisciplinary clinical assessment remain controlling.
Primary sources
- Exact Sciences: Explore the Results
- Exact Sciences: Why Colon Recurrence Score
- Official Stage II MMR-P sample report
- Official Stage III A/B sample report
- Gray et al., QUASAR validation
- Yothers et al., NSABP C-07 validation
- Clark-Langone et al., analytical performance
This page and calculator provide implementation-verified report interpretation, not independent clinical validation or medical advice.